Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human IGF-1R /CD221 Protein, 1mg  

Recombinant human IGF-1R /CD221 Protein, 1mg

Recombinant Human IGF1R /CD221 Protein (rhIGF1R) Glu31-Asn 932 was produced in human 293 cells (HEK293)

Synonym
Recombinant Human Protein, IGF-1R, IGF1R, CD221, IGFIR, IGFR, JTK13, MGC142170, MGC142172, MGC18216, Insulin-like Growth Factor 1 (IGF-1) Receptor

More details

IGR-H5229-1K

Availability: within 7 days

2 310,00 €

Background
The Insulin-like Growth Factor 1 Receptor (IGF1R) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.[1] The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.[2-3]

Source
Recombinant Human IGF1R /CD221 Protein (rhIGF1R) Glu31-Asn 932 (Accession # P08069 ) was produced in human 293 cells (HEK293).

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 104.8 kDa. The protein migrates as 90-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

References

(2) Jones JI, Clemmons DR (1995). Endocr. Rev. 16 (1): 3–34.
(3) LeRoith D, et al. (1995). Endocr. Rev. 16 (2): 143–63.